Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 9/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.50 |
| ▸ | TTR | P02766 | 3/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650636 | 0.92 | NQO2 (0.67) | NQO2PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL1650634 | 0.92 | NQO2 (0.67) | NQO2PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL1652049 | 0.91 | NQO2 (0.49) | NQO2PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL1650451 | 0.89 | MEN1 (0.59) | NQO2PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL1650240 | 0.83 | MEN1 (0.49) | NQO2PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL1651030 | 0.82 | NQO2 (0.54) | NQO2PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL1651028 | 0.82 | NQO2 (0.54) | NQO2PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL1654001 | 0.81 | MEN1 (0.47) | NQO2PTGS2PTGS1CYP1A1CYP1B1 | |
| SCHEMBL1650706 | 0.80 | NQO2 (0.51) | NQO2PTGS1CYP1A1CYP1B1KDM4E | |
| SCHEMBL1650710 | 0.80 | NQO2 (0.51) | NQO2PTGS1CYP1A1CYP1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112881-B2 | Skin lightening compounds | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170342047-A1 | Cancerous Cell Growth Inhibiting Compounds | WISYS TECHNOLOGY FOUNDATION, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170197897-A1 | Skin Lightening Compounds | WISYS TECH FOUND INC (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2016014529-A1 | SKIN LIGHTENING COMPOUNDS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-8530512-B2 | Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species | MONTE AARON P (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | MONTE AARON P | 2011-04-21 | — | — | US | disclosed |
| US-20070292545-A1 | ANTI-INFECTIVE AGENTS AND METHODS OF USE | WISYS TECHNOLOGY FOUNDATION | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342047-A1 | Cancerous Cell Growth Inhibiting Compounds | TYR, MKI67, MC1R | NQO2 224/4885PTGS2 284/4885PTGS1 203/4885 |
| US-10112881-B2 | Skin lightening compounds | TYR, MC1R, MCHR1 | NQO2 202/4885PTGS2 1158/4885PTGS1 508/4885 |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | ABCC1, H1-3, H1-2 | NQO2 91/4885PTGS2 630/4885PTGS1 681/4885 |
| US-20070292545-A1 | ANTI-INFECTIVE AGENTS AND METHODS OF USE | H1-3, H1-0, H1-2 | NQO2 28/4885PTGS2 1061/4885PTGS1 318/4885 |
| US-20170197897-A1 | Skin Lightening Compounds | TYR, MC1R, MCHR1 | NQO2 707/4885PTGS2 524/4885PTGS1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.